Covid-19 Vaccines: Safety

Debate between Andrew Bridgen and Caroline Johnson

Monday 24th October 2022 Westminster Hall

[The Parliamentary Under-Secretary of State for Health and Social Care (Dr Caroline Johnson)]

It is a pleasure to serve under your chairmanship, Sir Roger. I thank my hon. Friend the Member for Carshalton and Wallington (Elliot Colburn) for his kind words regarding the covid vaccine programme, and for bringing this important and timely debate to the House. It is timely because we started the covid-19 boosters autumn scheme just a few weeks ago.

Before I respond to the points that have been made in the debate and try to answer all the questions posed by right hon. and hon. Members, I thank Members—particularly those on the Opposition Benches, including the hon. Members for Denton and Reddish (Andrew Gwynne) and for Coatbridge, Chryston and Bellshill (Steven Bonnar)—for their support for the vaccine scheme. I also thank each and every person in the country who has come forward for their jabs, as well as the tens of thousands of NHS staff and volunteers who made that happen.

My hon. Friend the Member for Carshalton and Wallington asked why the vaccine programme had worked so well. It worked so well because of the dedication and hard work of all who were involved in it—from the Government to the NHS, and from the volunteers to pharma. I was honoured to volunteer alongside people from my local area as young as 15 and as old as in their 80s. It was truly a community effort.

The take-up of the covid-19 vaccine has been huge, and over 151 million vaccines have been delivered in the UK, meaning that more than 90% of people aged 12 and over have received at least one dose and more than 40 million have received a booster or third dose. We have also made a great start to the autumn booster campaign. Since the start of the campaign on 5 September, more than 10 million people in England have stepped forward for their jabs.

Our safe and effective vaccines have underpinned the Government’s strategy for living with covid-19. They have allowed the economy and society to reopen, and the country’s ability to live with the virus in the future will continue to depend on deeper and broader population immunity. Critically, they have also reduced the pressure on the national health service and allowed us to start to tackle the elective care backlog.

Vaccines remain our biggest line of defence as we head into a challenging winter period. Vaccinated people are less likely to get seriously ill with covid-19 or seasonal flu, or to be admitted to hospital, and there is also evidence that they are less likely to pass the virus on to others. We know the covid vaccine has saved tens of thousands of lives—that is tens of thousands of mothers, fathers, husbands, wives, sisters, brothers, sons and daughters who are thankfully still with us.

[Andrew Bridgen]

Is the Minister aware that excess deaths run somewhere—there are two different sets of figures—between 18,000 and 25,000 this year alone?

[Dr Johnson]

I am referring to the covid vaccine, which has saved hundreds of thousands of lives. I take my hon. Friend’s point, but there is no evidence that those deaths were caused by the covid vaccine. Let me acknowledge and pass on my sympathies to the very small number of people for whom vaccines may not have worked as intended, and who may have suffered an adverse reaction from vaccines.

I turn to vaccine safety. All vaccines used in the UK covid-19 vaccine programme are safe. In the UK we have some of the highest safety standards in the world. The MHRA is globally recognised for high standards of quality, safety and medicines regulation. Each covid-19 vaccine candidate is assessed by teams of scientists and clinicians on a case-by-case basis. There are extensive checks and balances at every stage of vaccine development. It is only once each potential vaccine has met robust standards of effectiveness, safety and quality set by the MHRA that it will be approved for use.

It is also important to stress that the surveillance of vaccine safety and adverse reactions does not stop once a vaccine has been approved. The MHRA and the UK Health Security Agency constantly review a wide range of available data on the safety of vaccines, including UK and international reports of adverse reactions.